Alvotech Eyes $450m Funding And Public Listing With SPAC Merger
Proposed Combination Would Have Initial Enterprise Value Of Around $2.25bn
Executive Summary
Eight years after its inception, pure-play biosimilars company Alvotech has announced plans to list on the NASDAQ via a SPAC merger that will deliver hundreds of millions in cash to fund product development and future growth.
You may also be interested in...
Who’s Hired? Teva Gets New Leadership In Canada
Teva has appointed a new general manager in Canada following the departure of Christine Poulin to Covis Pharma. At the same time, Amneal’s associate general counsel, Meredith Cook, has taken up a role at ANI Pharmaceuticals, while Alvotech has appointed several new directors to its board as part of its transition to being a publicly-listed company.
Icelandic Exchange Approves Alvotech As Its Shares Trade In NY
Alvotech is celebrating an “historic milestone” as it became a publicly listed company in New York, with its shares set to also trade in its domestic Iceland next week.
Alvotech On The Verge Of New Chapter As SPAC Merger Is Approved
Alvotech will cease to be a privately listed company next week, with its merger with special purpose acquisition company Oaktree Acquisition Corp. II set to close “on or about 15 June.”